首页> 美国卫生研究院文献>Oncology Letters >Hepatic blood flow by perfusion computed tomography as an imaging biomarker for patients with gastric cancer
【2h】

Hepatic blood flow by perfusion computed tomography as an imaging biomarker for patients with gastric cancer

机译:灌注计算机断层扫描术作为肝癌患者成像生物标志物的肝血流量

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Perfusion computed tomography (PCT) is a less invasive imaging modality that provides information about tissue hemodynamics at the capillary level. The present study aimed to investigate the correlation between hepatic perfusion and gastric cancer progression. A total of 136 patients with gastric adenocarcinoma were evaluated in the present study. Prior to initial treatment, liver PCT was performed across the hepatic hilar plane and the hepatic blood flow (HBF) was measured using the dual-input deconvolution method. HBF was compared with clinicopathological factors, patient prognosis and circulating serum proangiogenic cytokines. The median HBF was 217 ml/min/100 g tissue. Patients with high HBF had larger tumors (43 mm vs. 71, P<0.001) and more advanced tumor-node stages (P<0.001 for both). When both patient groups of operable and inoperable were compared by their respective median HBF values, each high-HBF group had a significantly worse prognosis (P=0.002 and P=0.024), notably in the inoperable group, with <1-year survival. In 17 postoperative recurrent patients, the high-HBF at recurrence group also had a significantly worse postrecurrent prognosis (P=0.019). HBF was an independent prognostic factor (hazard ratio, 2.019; P=0.048) and was strongly associated with serum vascular endothelial growth factor level (R=0.607, P<0.001). HBF was significantly correlated with gastric cancer progression, and is an easily measured imaging biomarker reflecting patient survival.
机译:灌注计算机断层扫描(PCT)是一种侵入性较小的成像方式,可提供有关毛细血管水平的组织血流动力学的信息。本研究旨在调查肝灌注与胃癌进展之间的相关性。本研究共评估了136例胃腺癌患者。在初始治疗之前,在肝门平面上进行肝PCT,并使用双输入解卷积方法测量肝血流量(HBF)。将HBF与临床病理因素,患者预后和循环血清促血管生成细胞因子进行比较。中位HBF为217 ml / min / 100 g组织。 HBF高的患者肿瘤更大(43 mm vs. 71,P <0.001)和晚期肿瘤淋巴结分期(两者均P <0.001)。当将可手术和不可手术的两个患者组的各自中位HBF值进行比较时,每个高HBF组的预后均显着较差(P = 0.002和P = 0.024),特别是在不可手术组中,其<1年生存期。在17例术后复发患者中,高HBF复发组的复发后预后也明显较差(P = 0.019)。 HBF是一个独立的预后因素(危险比2.019; P = 0.048),与血清血管内皮生长因子水平密切相关(R = 0.607,P <0.001)。 HBF与胃癌的进展显着相关,是一种易于测量的影像生物标志物,可反映患者的生存情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号